$0.44
3.48% yesterday
Nasdaq, Dec 02, 10:16 pm CET
ISIN
US8006771062
Symbol
SGMO

Sangamo Therapeutics, Inc. Stock price

$0.44
-0.14 23.88% 1M
-0.03 6.91% 6M
-0.58 56.84% YTD
-1.92 81.35% 1Y
-3.21 87.94% 3Y
-9.54 95.59% 5Y
-8.63 95.15% 10Y
-3.50 88.83% 20Y
Nasdaq, Closing price Tue, Dec 02 2025
+0.01 3.48%
ISIN
US8006771062
Symbol
SGMO
Industry

Key metrics

Basic
Market capitalization
$143.1m
Enterprise Value
$113.5m
Net debt
positive
Cash
$29.6m
Shares outstanding
322.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.4 | 1.9
EV/Sales
3.5 | 1.5
EV/FCF
negative
P/B
22.9
Financial Health
Equity Ratio
22.4%
Return on Equity
-430.1%
ROCE
-283.1%
ROIC
-302.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$32.9m | $74.3m
EBITDA
$-104.8m | $-35.9m
EBIT
$-109.0m | $-72.4m
Net Income
$-108.9m | $-95.6m
Free Cash Flow
$-76.4m
Growth (TTM | estimate)
Revenue
-37.7% | 28.5%
EBITDA
36.0% | 61.5%
EBIT
35.6% | 26.2%
Net Income
40.8% | 2.4%
Free Cash Flow
34.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-318.7% | -48.3%
EBIT
-331.6%
Net
-331.3% | -128.8%
Free Cash Flow
-232.4%
More
EPS
$-0.4
FCF per Share
$-0.2
Short interest
3.5%
Employees
183
Rev per Employee
$320.0k
Show more

Is Sangamo Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,078 stocks worldwide.

Sangamo Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Sangamo Therapeutics, Inc. forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Sangamo Therapeutics, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Sangamo Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
33 33
38% 38%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 37 37
35% 35%
113%
- Research and Development Expense 105 105
37% 37%
319%
-105 -105
36% 36%
-319%
- Depreciation and Amortization 4.24 4.24
26% 26%
13%
EBIT (Operating Income) EBIT -109 -109
36% 36%
-332%
Net Profit -109 -109
41% 41%
-331%

In millions USD.

Don't miss a Thing! We will send you all news about Sangamo Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sangamo Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 14 hours ago
RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain.
Neutral
GlobeNewsWire
12 days ago
RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo's request for a rolling submission and review of the Biologics License Application (BLA) for isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treat...
Neutral
Seeking Alpha
26 days ago
Sangamo Therapeutics, Inc. ( SGMO ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Louise Wilkie - Head of Global Corporate Communications & Investor Relations Alexander Macrae - CEO, President & Director Nathalie Dubois-Stringfellow - Senior VP & Chief Development Officer Prathyusha Duraibabu - Interim Principal Financial Officer Gregory Davis - Head of Research & Tech...
More Sangamo Therapeutics, Inc. News

Company Profile

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Head office United States
CEO Alexander Macrae
Employees 183
Founded 1995
Website www.sangamo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today